HIV-associated neurocognitive disorders (HAND)

Israel Medical Association Journal

Volumn 17, Issue 1, 2015, Pages 54-59

  Elbirt, Daniel ^a   Mahlab Guri, Keren ^a   Bezalel Rosenberg, Shira ^a   Gill, Harpreet ^b   Attali, Malka ^a   Asher, Ilan ^a  

^a HEBREW UNIVERSITY   (Israel)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

AIDS; AIDS dementia; Highly active antiretroviral therapy (HAART); HIV associated neurocognitive disorders (HAND); Human immunodeficiency virus (HIV)

Indexed keywords

ABACAVIR; ATAZANAVIR; BRAIN DERIVED NEUROTROPHIC FACTOR; CD14 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR5; DARUNAVIR; DELAVIRDINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; MARAVIROC; MONOCYTE CHEMOTACTIC PROTEIN 1; NEVIRAPINE; RALTEGRAVIR; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; TENOFOVIR; TUMOR NECROSIS FACTOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALTERNATIVE MEDICINE; AMNESIA; ATTENTION DISTURBANCE; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEMENTIA ASSESSMENT; DRUG RESISTANCE; EMOTIONAL DISORDER; FUNCTIONAL DISEASE; GENETIC PREDISPOSITION; GERIATRIC DISORDER; GROOVED PEGBOARD TEST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HIV DEMENTIA SCALE; HOPKINS VERBAL LEARNING TEST; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INTERNATIONAL HIV DEMENTIA SCALE; LEARNING AND MEMORY TEST; MIXED INFECTION; MONTREAL COGNITIVE ASSESSMENT; NERVE DEGENERATION; OPPORTUNISTIC INFECTION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; VIRAL LOAD TESTING; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS; VIRUS REPLICATION; AIDS DEMENTIA COMPLEX; COGNITION DISORDERS; COMPLICATION; HIV INFECTIONS; HUMAN; PATHOPHYSIOLOGY; PROCEDURES; VIROLOGY;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; HIV INFECTIONS; HUMANS;

EID: 84921842338     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. De Cock KM, Jaffe HW, Curran JW. The evolving epidemiology of HIV/AIDS. AIDS 2012; 26: 1205-13.
2. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIVassociated neurocognitive disorders. Neurology 2007; 69: 1789-99.
3. Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIVassociated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013; 56: 1004-17.
4. Letendre SL, Ellis RJ, Ances BM, Mc-Cutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med 2010; 18: 45-55.
5. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17: 3-16.
6. Letendre SL. Central Nervous System Complications in HIV Disease: HIVAssociated Neurocognitive Disorder. Top HIV Med 2011; 19: 137-42.
7. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virusassociated neurocognitive disorders: Mind the gap. Ann Neurol 2010; 67: 699-714.
8. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243-50.
9. Kaul M. HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol 2009; 22: 315-20.
10. Lindl KA, Marks DR, Kolson DL, Jordan-Sciutto KL. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol 2010; 5: 294-309.
11. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.
12. Albright AV, Soldan SS, Gonzalez-Scarano F. Pathogenesis of human immunodeficiency virus-induced neurological disease. J Neurovirol 2003; 9: 222-7.
13. Gorry PR, Ong C, Thorpe J, et al. Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res 2003; 1: 463-73.
14. O'Donnell LA, Agrawal A, Jordan-Sciutto KL, Dichter MA, Lynch DR, Kolson DL. Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. J Neurosci 2006; 26: 981-90.
15. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410: 988-94.
16. Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE. Betachemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 1998; 44: 831-5.
17. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3: e2516.
18. Ryan LA, Zheng J, Brester M, et al. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis 2001; 184: 699-706.
19. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 2002; 99: 13795-800.
20. Letendre S, Rosario D, Ellis R, Potter M, Woods SP. Higher levels of phosphorylated tau in CSF are associated with HIV infection, older age, antiretroviral use, and worse prospective memory. [Abstract 406.] 18th Conference on Retroviruses and Opportunistic Infections (CROI). 2011, Boston, USA.
21. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25: 1747-51.
22. Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007; 196: 361-70.
23. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 273-8.
24. Bottiggi KA, Chang JJ, Schmitt FA, et al. The HIV Dementia Scale: Predictive power in mild dementia and HAART. J Neurolog Sci 2007; 260: 11-15.
25. Skinner S, Adewale AJ, Deblock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: Comparative performance among patients exposed to antiretroviral therapy. HIV Med 2009; 10: 246-52.
26. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243-50.
27. Morgan EE, Woods SP, Scott JC, et al.; the HIV Neurobehavioral Research Center (HNRC) Group. Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol 2008; 30: 83-90.
28. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005; 19: 1367-74.
29. Njamnshi AK, Djientcheu VDP, Fonsah JY, et al. The International HIV Dementia Scale is a useful screening tool for HIV-associated dementia/cognitive impairment in HIV-infected adults in Yaounde, Cameroon. J Acquir Immune Defic Syndr 2008; 49: 393-7.
30. Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol 2004; 18: 234-48.
31. European AIDS Clinical Society. Guidelines for treatment of HIV infected adults in Europe. http://www. europeanaidsclinicalsociety. org. Accessed May 5, 2013.
32. Letendre S, Marquie-Beck J, Capparelli E, et al.; the CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
33. Letendre S, FitzSimons C, Ellis R, et al. Correlates of CSF viral loads in 1221 volunteers of the CHARTER cohort. [Abstract 172.] 17th Conference on Retroviruses and Opportunistic Infections (CROI). 2010, San Francisco, USA.
34. Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 2009; 19: 169-85.
35. Joska JA, Gouse H, Paul RH, et al. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010; 16: 101-14.
36. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23: 1359-66.
37. Yilmaz A, Watson V, Else L, Gissl'n M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009; 23: 2537-40.
38. Letendre SL, Marquie-Beck J, Ellis RJ, et al. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007; 2: 120-7.